Drug Trial Radar · NCT07354932
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Mar 9, 2026
Primary completion
Apr 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.
Conditions
- Primary IgA Nephropathy
Interventions
SHR-2173 injectionDrug
SHR-2173 injection;High dose
SHR-2173 injectionDrug
SHR-2173 injection;Medium dose
SHR-2173 injectionDrug
SHR-2173 injection;Low dose
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 24-hour Urine Protein-to-Creatinine Ratio (UPCR) at Week 24.Time frame: Week 24.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.